Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2017 Oct;39(7):555–559. doi: 10.1097/MPH.0000000000000968

Table II. CD4 Counts (n=23).

Above lower limit of normal:
  • n = 22, CD4 count range 386-2688 cells/μL

  • Test performed a median of 34 days after OAC

  • Received 3-6 cumulative cycles of OAC

  • 12 received IV chemotherapy prior to OAC


Below normal:
  • n = 1, CD4 count 189 cells/μL after IV chemotherapy and during OAC

  • Prior treatment: 2 cycles of IV carboplatin and 3 cycles of OAC at time of testing (cumulative melphalan dose 9mg or 1.3mg/kg, cumulative topotecan 0mg, cumulative carboplatin 80mg or 11.6mg/kg)

  • CD4 count and abnormal mitogen level normalized through continued OAC treatment and remained normal at completion of OAC treatment